Patrick Campbell

FDA expands Vonvendi approval for all von Willebrand disease types, enhancing treatment options for adults and children with this rare condition.

Alnylam Pharmaceuticals debuts phase 2 KARDIA-3 data at ESC 2025 and advances zilebesiran into a phase 3 outcomes trial.

Olezarsen shows promise in significantly lowering triglyceride levels in patients with hypertriglyceridemia.

Discover key advancements in endocrinology from July 2025, including FDA approvals and trial results.

July delivered 9 impactful advancements across the gamut of disciplines in cardiology.

Clinicians explore the evolving landscape of asthma and COPD treatment, emphasizing the role of biologics and biomarkers in personalized patient care.

FDA approves aceclidine ophthalmic solution 1.44%, revolutionizing presbyopia treatment for millions with a once-daily eye drop.

FDA approves delgocitinib cream, offering a new treatment option for adults with moderate-to-severe chronic hand eczema.

Finerenone gains FDA approval for heart failure treatment, offering new hope for patients with reduced ejection fraction and improving care options.

Our recap of Q2 2025 in cardiology spotlights 3 FDA headlines, trial news, and new episodes of Don't Miss a Beat.

Explore key advancements in endocrinology from Q2 2025, including FDA approvals and groundbreaking diabetes research shaping future treatments.

June 2025 highlights groundbreaking advancements in endocrinology, featuring key insights from major conferences on diabetes, heart health, and kidney care.

Our June 2025 recap highlights significant advancements in cardiology, including new drug approvals and pivotal trial results.

Discover groundbreaking FDA approvals in 2025 that redefine treatment standards, enhance patient care, and address critical public health needs.

Mifepristone shows promise in improving glycemic control and reducing weight in patients with hypercortisolism and type 2 diabetes.

Maridebart cafraglutide shows potential as a monthly treatment for obesity and type 2 diabetes, demonstrating significant weight loss and glycemic improvements.

A new study reveals once-weekly efsitora alfa effectively lowers blood glucose in type 2 diabetes.

A global study reveals that universal access to semaglutide could save 28 million lives and significantly reduce obesity and diabetes worldwide.

CagriSema shows weight loss results in recent trials comparable to existing interventions.

A phase 3 trial reveals ecnoglutide significantly reduces body weight in overweight patients, showcasing its potential as a novel obesity treatment.

New findings reveal semaglutide significantly enhances walking ability and quality of life for patients with T2D and PAD.

A new study reveals hybrid closed-loop technology significantly improves glucose control for pregnant women with T1D.

Semaglutide 7.2 mg shows promising results, achieving a mean 21% weight loss in obesity treatment.

The ACHIEVE-1 trial reveals orforglipron's potential as a breakthrough treatment for type 2 diabetes.

New research reveals amycretin's promising potential for weight loss in obesity treatment, advancing to phase 3 trials for effective management options.

The FDA-cleared DermaSensor shows promise for skin cancer detection in primary care.

A recap of 3 Kidney Compass podcast episodes recorded at ERA 2025, including summaries and preview clips.

A recap of 5 studies to know from the ERA 2025 Congress, including expert perspectives.

A recent meta-analysis reveals GLP-1 RAs significantly reduce adverse kidney outcomes, highlighting their potential in chronic kidney disease management.